Definium Therapeutics, Inc. Cash Flow Conversion Efficiency
Definium Therapeutics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) has a cash flow conversion efficiency ratio of -0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.78 Million) by net assets ($918.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Definium Therapeutics, Inc. (2015–2025)
Cash flow conversion efficiency of Definium Therapeutics, Inc. from 2015 to 2025. This chart illustrates how Definium Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Definium Therapeutics, Inc. stock price today for real-time trading data and today's change.
Definium Therapeutics, Inc. Cash Flow Conversion Ratio Explained
Definium Therapeutics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Definium Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Definium Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see Definium Therapeutics, Inc. (DFTX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mega Or
TA:MGOR
|
0.003x |
|
Union Bank of Taiwan Pref
TW:2838A
|
0.018x |
|
Kilroy Realty Corp
NYSE:KRC
|
0.014x |
|
Novanta Inc
F:1GSN
|
0.011x |
|
Beijing Compass Technology Develop
SHE:300803
|
0.264x |
|
Emmi AG
SW:EMMN
|
0.189x |
|
Gitlab Inc
NASDAQ:GTLB
|
0.044x |
|
Gentex Corporation
NASDAQ:GNTX
|
0.073x |
Annual Cash Flow Conversion Efficiency for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual cash flow conversion efficiency of Definium Therapeutics, Inc. from 2015 to 2025. Review DFTX free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $332.33 Million | $-131.56 Million | -0.396x | -20.79% |
| 2024-12-31 | $241.45 Million | $-79.13 Million | -0.328x | +60.22% |
| 2023-12-31 | $78.13 Million | $-64.36 Million | -0.824x | -147.95% |
| 2022-12-31 | $150.92 Million | $-50.14 Million | -0.332x | -9.96% |
| 2021-12-31 | $151.66 Million | $-45.82 Million | -0.302x | +2.86% |
| 2020-12-31 | $75.87 Million | $-23.60 Million | -0.311x | -309.18% |
| 2019-12-31 | $2.74 Million | $-208.12K | -0.076x | +62.91% |
| 2018-12-31 | $3.52 Million | $-722.45K | -0.205x | -21.47% |
| 2017-12-31 | $3.95 Million | $-665.98K | -0.169x | +19.37% |
| 2016-12-31 | $127.28K | $-26.64K | -0.209x | -27.73% |
| 2015-12-31 | $284.17K | $-46.56K | -0.164x | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more